)
INNOVATE (VATE) investor relations material
INNOVATE Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 consolidated revenue rose 74.2% year-over-year to $421.6M, driven by record Infrastructure segment performance, while Life Sciences and Spectrum saw declines.
Net income attributable to shareholders was $10.4M ($0.71 per diluted share), reversing a prior-year loss of $22M.
Adjusted EBITDA increased to $46.3M from $15.7M year-over-year, led by Infrastructure and Life Sciences improvements.
Strategic actions included major refinancing, a pending sale of a controlling interest in Broadcasting to CONX Corp., and ongoing asset disposition processes.
DBMG delivered record results, MediBeacon expanded commercial momentum, and R2 Technologies showed strong global demand but faced liquidity constraints.
Financial highlights
Infrastructure revenue increased 77.6% to $414M, with Adjusted EBITDA up to $48.7M from $19.3M year-over-year.
Life Sciences revenue declined 31.3% to $2.2M, mainly due to lower R2 unit sales; Adjusted EBITDA losses narrowed.
Spectrum/Broadcasting revenue was $5.4M, with Adjusted EBITDA of $0.4M, impacted by network terminations.
Cash and equivalents were $87.8M as of June 30, 2026, down from $108.2M at year-end 2025.
Total principal outstanding indebtedness was $626.4M, up from $617.5M at year-end 2025.
Outlook and guidance
DBMG expects continued backlog growth and strong revenue visibility into 2027–2028, supported by a robust pipeline and secular demand trends.
Life Sciences aims to expand commercial placements, reimbursement, and clinical validation for MediBeacon, with pivotal clinical studies for TGFR Sensor targeted in 2027.
R2 anticipates further global expansion and is seeking additional capital to support scaling and commercial growth.
Management expects substantial changes to business, cash flow, and financial position due to ongoing asset sales and debt restructuring.
Substantial doubt exists about the ability to continue as a going concern due to upcoming debt maturities and liquidity risks.
- All proposals passed, directors elected, and no questions raised during the Q&A session.VATE
AGM 202611 Jun 2026 - Revenue up 33% to $364.8M, net loss narrowed, but debt maturities pose going concern risk.VATE
Q1 202620 May 2026 - Annual meeting to vote on directors, compensation, equity plan, and auditor ratification.VATE
Proxy filing28 Apr 2026 - Board recommends FOR all proposals, with focus on growth, governance, and executive alignment.VATE
Proxy filing28 Apr 2026 - Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 202526 Mar 2026 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 20242 Feb 2026 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 202416 Jan 2026 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance after major 2024 changes.VATE
Proxy Filing2 Dec 2025
Next INNOVATE earnings date
Next INNOVATE earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)